Silence Therapeutics Plc ADR Dossier
Qualitative Analysis
Business overview
Silence Therapeutics plc is a global clinical-stage biotechnology company dedicated to discovering and developing precision-engineered medicines using its proprietary short interfering RNA (siRNA) platform, mRNAi GOLD™ (GalNAc Oligonucleotide Discovery). The company's technology is designed to target and silence disease-associated genes in the liver, addressing high unmet medical needs across hematology, cardiovascular disease, and rare diseases. Silence's wholly owned pipeline is led by divesiran (SLN124), a first-in-class siRNA targeting TMPRSS6 for the treatment of polycythemia vera (PV), and zerlasiran (SLN360), a Phase 3-ready siRNA targeting LPA to reduce cardiovascular risk in individuals with high lipoprotein(a). Additionally, the company maintains strategic research and development collaborations with major pharmaceutical partners, including AstraZeneca.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing clinical investment in divesiran (SLN124), a potential first-in-class siRNA for polycythemia vera (PV) and other hematological disorders [1.4.2].
Expected impact: Establish a compelling therapeutic profile with reduced phlebotomy requirements and improved quality of life.
Seeking a strategic third-party partner to advance Phase 3 development and future commercialization of zerlasiran (SLN360) for cardiovascular disease associated with high Lp(a).
Expected impact: Leverage partner resources to fund and execute large-scale Phase 3 trials while extending Silence's cash runway.
Advancing extra-hepatic cell targeting capabilities leveraging the proprietary mRNAi GOLD platform.
Expected impact: Expand the therapeutic reach of the siRNA platform beyond liver-targeted diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborative development of siRNA therapies for cardiovascular, renal, metabolic, and respiratory diseases using Silence's mRNAi GOLD platform [1.2.4]. Note: AstraZeneca returned global rights to SLN312 in March 2026, but the broader platform collaboration remains active.
Terms: Includes option fees and milestone payments (e.g., $10M option fee in 2023 and $10M clinical initiation milestone in 2024).
Collaboration established in October 2021 to develop siRNAs for three undisclosed targets leveraging Silence's proprietary platform.
Terms: Potential milestone payments and royalties on future sales.